ClinicalTrials.Veeva

Menu

The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels

G

Guangzhou University of Traditional Chinese Medicine

Status and phase

Unknown
Phase 4

Conditions

Cerebral Infarction

Treatments

Drug: Erigeron Injection
Drug: placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT01926834
1201/01/006284

Details and patient eligibility

About

To study the effects of Erigeron Injection on human serum VEGF, MMP-9 and EPC levels after acute cerebral infarction,test is made by random double-blind controlled.patients with acute cerebral infarction were divided randomly into erigeron injection+aspirin group,aspirin group,and health people. The main indexes are the serum level of VEGF, MMP-9 and EPC.The review is made by the reference to NIHSS and so on. So, Erigeron Injection have the function of promoting angiogenesis in multiple targets through this test.

Full description

OBJECTIVE:

To study the effects of Erigeron Injection on human serum VEGF, MMP-9 and EPC levels after acute cerebral infarction.

METHOD:

40 patients with acute cerebral infarction(in accordance with the inclusion criteria) were divided randomly into erigeron injection+aspirin group,aspirin group,and 20 health people. Erigeron injection+aspirin group and aspirin group drew peripheral blood on the prior treatment,the posttreatment 1th, 3th and 7th day,and tested the level of VEGF, MMP-9 and EPC.Tested the health people one time.

Enrollment

60 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • patients aged no younger than 18yrs
  • attack within 72 hours
  • NIHSS score in the 2-25 points
  • Ischemic Stroke occurred for the first time, or with a history of stroke disease but without sequelae
  • Signed the informed consents

Exclusion criteria

  • patients aged younger than 18yrs
  • Patients with tumor, coronary heart disease, valvular heart disease, psoriasis, rheumatism, hematologic diseases, infertility, varieties of acute inflammation
  • Patients with severe cognitive impairment
  • Refused to cooperate or been unable to cooperation for neurological disorders
  • Cerebral hemorrhage or hemorrhagic cerebral infarction
  • Unstable vital signs dued to massive cerebral infarction
  • Patients with serious heart, liver and renal insufficiency

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

60 participants in 3 patient groups, including a placebo group

Erigeron Injection
Experimental group
Description:
Erigeron Injection, 30ml,qd,i.v., for 7 days
Treatment:
Drug: Erigeron Injection
placebo
Placebo Comparator group
Description:
normal saline, 500ml,i.v.,qd, for 7 days
Treatment:
Drug: placebo
health volunteers
No Intervention group
Description:
health volunteers, no drug to be given.

Trial contacts and locations

0

Loading...

Central trial contact

Jianwen Guo, doctor; Yefeng Cai, master

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems